Mammary epithelium-specific inactivation of V-ATPase reduces stiffness of extracellular matrix and enhances metastasis of breast cancer

Gajendra K. Katara1, Arpita Kulshrestha1, Liquin Mao1, Xin Wang2, Manoranjan Sahoo1, Safaa Ibrahim1, Sahithi Pamarthy1, Kimiko Suzue3,4, Gajendra S. Shekhawat2, Alice Gilman-Sachs1 and Kenneth D. Beaman1

1 Department of Microbiology and Immunology, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA
2 Department of Materials Science and Engineering, Northwestern University, Evanston, IL, USA
3 Department of Pathology, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA
4 Advocate Lutheran General Hospital, Park Ridge, IL, USA

Keywords
atomic force microscopy; ATP6V0a2; breast cancer metastasis; extracellular matrix stiffness; glycosylation; V-ATPase

Correspondence
K. D. Beaman, Department of Microbiology and Immunology, Chicago Medical School, Rosalind Franklin University of Medicine and Science, 3333 Green Bay Road, N. Chicago, IL 60064, USA
Fax: +1 847 775 6506
Tel: +1 847 578 3444
E-mail: kenneth.beaman@rosalindfranklin.edu
(Received 5 July 2017, revised 25 September 2017, accepted 7 November 2017, available online 12 December 2017)
doi:10.1002/1878-0261.12159

Extracellular matrix (ECM) critically impacts tumor progression and is influenced by both cancer and host tissue cells. While our understanding of cancer cell ECM remodeling is widespread, the importance of host tissue ECM, which provides initial congenial environment for primary tumor formation, is partly understood. Here, we report a novel role of epithelial cell-associated vacuolar ATPase ‘a2’ isoform (a2V) in regulating breast tissue ECM stiffness to control metastasis. Using a mammary gland-specific a2V-knockout model, we show that in the absence of a2V, breast tumors exhibit atypically soft tumor phenotype, less tumor rigidity, and necrotic tumor microenvironment. These tumors contain a decreased number of cancer cells at primary tumor site, but showed extensive metastases compared to control. Nanomechanical evaluation of normal breast tissues revealed a decrease in stiffness and collagen content in ECM of a2V-deleted breast tissues. Mechanistically, inhibition of a2V expression caused dispersed Golgi morphology with relocation of glycosyltransferase enzymes to early endosomes in mammary epithelial cells. This resulted in defective glycosylation of ECM proteins and production of compromised ECM that further influenced tumor metastasis. Clinically, in patients with cancer, low a2V expression levels in normal breast tissue correlated with lymph node metastasis. Thus, using a new knockout mouse model, we have identified a2V expression in epithelial cells as a key requirement for proper ECM formation in breast tissue and its expression levels can significantly modulate breast tumor dissemination. Evaluation of a2V expression in normal breast tissues can help in identifying patients with high risk of developing metastases.
1. Introduction

The local microenvironment or niche around tumors plays a significant role in initiating and encouraging tumor invasion and metastasis. A successful metastasis requires a local niche to support cancer cell proliferation and formation of a primary tumor. This niche contains blood cells, immune cells, fibroblasts, endothelial cells, and extracellular matrix (ECM) (Bonnans et al., 2014; Liotta and Kohn, 2001). ECM is a complex network of macromolecules with distinct biological and mechanical properties and regulates the cellular behavior directly or indirectly (Lu et al., 2011). In cancer, ECM architecture can influence disease outcome before and during the disease conditions (Lu et al., 2012). For example, overexpression of hyaluronan synthase-2 causes high molecular mass hyaluronan production in ECM that protects against malignant tumor progression (Tian et al., 2013). During cancer, ECM remodeling occurs through rearrangement, cross-linking, and deposition as well as degradation of certain ECM proteins (Paszek et al., 2005). This remodeling of ECM has been suggested as a pathway rather than an obstacle for cancer metastasis (Lu et al., 2011, 2012). Nevertheless, the molecules that can influence ECM organization in normal condition can be of immense importance in cancer prognosis or therapeutics. V-ATPase regulates metastasis by ECM remodeling

Vacuolar (V)-ATPases are the multi-subunit proton pumps present on vesicular membranes of normal cells and maintain intracellular pH. In cancer cells, V-ATPases are required on the cell surface where they actively participate in growth, metastasis, and chemoresistance (Forgac, 2007; Kulshrestha et al., 2015, 2016; Smith et al., 2016; Stransky et al., 2016). Several V-ATPase subunits have multiple isoforms that exhibit cell- and tissue-specific expression, thereby contributing to a variety of physiological activities within the cell (Breton and Brown, 2013; Smith et al., 2003). In humans, mutations in the ATP6V0a2 gene, which encodes V-ATPase ‘a2’ isoform (a2V), lead to glycosylation defects of serum proteins and cause the autosomal recessive cutis laxa (ACRL) skin syndrome (Guillard et al., 2009; Kornak et al., 2008). Inhibition of a2V expression in mammary epithelial cells causes impairment in cell proliferation through Notch and TGF signaling (Pamarthy et al., 2016).

In cancer, we have reported the role of cancer cell-associated a2V in promoting protumorigenic macrophage phenotype in the breast tumor microenvironment (Katara et al., 2014, 2016). However, the precise role of V-ATPase in host tissue microenvironment during breast cancer dissemination is not clear. In this study, using an a2V-knockout mouse model, we show that the inhibition of V-ATPase expression in mammary epithelial cells modulates the ECM architecture that directly affects breast cancer phenotype and metastasis in transplant tumor model. We demonstrate that deletion of a2V gene (ATP6V0a2) in mouse mammary glands leads to a reduction in glycosylation of ECM proteins that causes stiffness-related alterations in breast tissue ECM. Upon tumor transplantation, these mice display an atypically soft, highly inflammatory and metastatic breast tumor phenotype. We also show the clinical significance of our results in patients with cancer where a2V expression levels in normal breast tissues inversely correlate with the metastasis incidence.

2. Materials and methods

2.1. Targeted disruption of the Atp6v0a2 gene and mice

Floxed ATP6v0a2 (a2Vfl/fl) mice were generated as described before (Pamarthy et al., 2016). For conditional removal of ATP6v0a2 gene, a2Vfl/fl mice were crossed with MMTVCre transgenic mice (Jackson Laboratories, Bar Harbor, ME, USA) resulting in a2Vfl/fl−MMTVCre mice. The MMTVCre transgenic mice carry Cre recombinase under the control of regulatory promoter for the mouse mammary tumor virus (MMTV) long terminal repeat, which is specifically expressed in mammary epithelium. The presence of a2Vfl gene was confirmed by PCR using the following primers: forward 5′-AGGGTGGTGTCCTTTCACTCT and reverse 5′-ATCCCCAGGATCCACGCAT (Fig. 1C). Further, a2Vfl/fl−MMTVCre mice were backcrossed with a2Vfl/fl mice in order to obtain a2Vfl/fl−MMTVCre mice in which ATP6v0a2 was specifically removed in mammary glands. Breast tissues from a2Vfl/fl−MMTVCre and a2Vfl/fl mice were used for ATP6v0a2 RNA and protein analyses. All the animal experiments were performed in accordance with the Institutional Animal Care and Use Committee of the Rosalind Franklin University of Medicine and Science, North Chicago, Illinois.

2.2. Antibodies and reagents

Monoclonal anti-a2V Ab was generated as described previously (Derks and Beaman, 2004). Rabbit polyclonal anti-CK14 Ab, anti-TNF-α, anti-collagen IV Ab, anti-laminin1 + 2 Ab, anti-GL25D2 Ab, Mu monoclonal anti-EAA-1 Ab and mouse anti-β-actin Ab were purchased from Abcam (Cambridge, MA, USA); rabbit anti-GAPDH was from Cell Signaling (Danvers, MA, USA); and rabbit polyclonal anti-giantin Ab from Biolegend (San Diego, CA, USA).
mouse IgG isotype controls were purchased from Sigma (St Louis, MO, USA). EnVision+Dual Link System-HRP polymer was obtained from DAKO (Glostrup Municipality, Denmark) and Alexa Fluor® 488 and/or Alexa Fluor® 594-conjugated secondary antibody was purchased from Invitrogen. Permount from Fisher scientific and ProLong® Gold containing DAPI (Invitrogen, Grand Island, NY, USA) were used as mounting media.

2.3. Cell lines and tissue samples

Mouse E0771 cells (CH3 Biosystems, Amherst, NY, USA) and Py230 mouse mammary carcinoma (ATCC, Manassas, VA, USA) were used for transplanting tumors in mice. E0771 was maintained as a monolayer in RPMI 1640 (Invitrogen) supplemented with 10% bovine serum, 100 U·mL⁻¹ penicillin, 100 U·mL⁻¹ streptomycin, and 10 mM HEPES buffer at 37 °C and 5% CO₂. F12K medium (ATCC) was used for culturing Py230 cell line. Human mammary primary epithelial cells (HMEpC) (Cell Application, San Diego, CA, USA) were cultured in human mammary epithelial cell growth medium in the above-mentioned conditions. Commercially available human breast tumor and matched normal breast tissue paraffin sections were procured from BioChain. GFP-expressing E0771 cells were generated by transfecting with a phCMV-GFP fusion stable vector (Genlantis, San Diego, CA, USA) and procedures according to the manufacturer’s instructions.
2.4. Isolation of mammary epithelial cells

Mammary glands were dissected from female mice and were minced and dissociated enzymatically at 37 °C for 2 h in culture medium (DMEM/F12) containing 2% fetal bovine serum supplemented with 300 U·mL⁻¹ collagenase and 100 U·mL⁻¹ hyaluronidase ( Stem Cell Technologies, Vancouver, Canada). The resulting cell suspension was suspended in 0.25% trypsin/EDTA for 2 min and centrifuged (250 g for 10 min). The resulting pellets were digested at 37 °C for 1 h in culture medium supplemented with dispase (2 mg·mL⁻¹) and DNase (0.1 mg·mL⁻¹) ( STEM Cell Technologies). Dissociated cells were then depleted of red blood cells by suspending in RBC lysis buffer for 3 min and finally filtered through a 40-mm mesh.

2.5. Histology, immunohistochemistry, and immunofluorescence

Tissue sections of 5 μm size from the fixed frozen breast tumors and paraffin-embedded normal breasts were used. For histology, sections were stained with Mayer’s hematoxylin and 0.1% eosin. Immunohistochemistry (IHC) was performed using Dako EnVision+ HRP-DAB system in accordance with the manufacturer’s instructions. Briefly, fixed frozen sections were boiled in sodium citrate buffer (pH = 6.0) for antigen retrieval. These sections were blocked for endogenous peroxidase activity by using dual peroxidase block and for protein blocking by using 5% BSA. Tissue sections were incubated with primary antibodies overnight at 4 °C followed by washing with PBST and incubation with secondary antibody polymer for 20 min at room temperature. DAB was used as a chromogen to detect secondary antibodies in 3% FBS in PBS for 45 min at room temperature. The cells were again rinsed with PBST and mounted with ProLong® Gold mounting medium containing DAPI and allowed to polymerize at room temperature for 24 h. Cells were visualized and imaged in Nikon Eclipse TE2000-S fluorescence microscope. Images were analyzed using Nikon NIS-Element software.

2.6. Atomic force microscopy (AFM)

Experimental procedures for AFM were followed from recently published studies on AFM use in measuring tissue stiffness (Plodinec et al., 2012). Excised tumor or normal breast tissue sections were collected and stored in ice-cold Ringer’s buffer. AFM was performed same or next day of tissue collection. Tissues were immobilized and flattened on petri plate using all-purpose Krazy glue. AFM force measurements were taken at room temperature using a BioScope Resolve AFM (Bruker, Billerica, MA, USA) integrated onto an Axio Observer.D1m (Carl Zeiss, Oberkochen, Germany) inverted optical microscope. Detailed methodology of AFM analysis is provided in the Supporting Information. AFM force measurements were taken at room temperature using a BioScope Resolve AFM (Bruker) integrated onto an Axio Observer.D1m (Carl Zeiss) inverted optical microscope. The system allowed precise lateral positioning of the silicon nitride AFM probe over the target position. To reduce stress on tissues during AFM mechanical measurement, smooth-curved colloidal probe was used for elasticity measurements with a diameter of ~ 900-nm SiO₂ bead and ~ 30-nm gold coating on the backside of the silicon nitride triangular cantilever (Novoscan Technologies, Ames, IA, USA). The deflection sensitivity was calibrated by repeated contact mode indentation on a clean glass slide (VWR International, Radnor, PA, USA) in PBS and the spring constant of the compliant AFM cantilever was measured to be $k = \sim 0.0635 \text{ N·m}^{-1}$ by thermal noise method (Hutter and Bechhoefer, 1993). The tip radius was determined postmortem by scanning electron microscope (SEM Hitachi SU8030). The loading–unloading process was conducted at about 1.5 μm·s⁻¹ and accomplished within roughly 1 s, during which the
applied load, \( F \), was measured as a function of the vertical actuation displacement of the piezoelectric cell, \( \delta_c \), with 1024 data points collected. A maximum load of \(~ 2 \) nN was applied at each data point, in order to keep the indentations within the elastic range.

The AFM cantilever with spring constant of \( k \), connected to the piezoelectric cell, is used to deform the tissue, while the interaction force, \( F \), is detected based on the deflection of the cantilever, \( \delta_c \). The raw AFM data are the relationship between force, \( F \), and piezoelectric cell displacement, \( \delta \), where \( F = k \times \delta_c \). As the AFM cantilever is compliant, it is bending into the tissue, while the interaction force, \( F \), is used to deform the tissue, and piezo-actuation displacement of the piezoelectric cell, \( \delta \), then the sample is deflected by \( \delta \). Thus, raw AFM force-displacement between \( (F \text{ vs. } \delta) \) needs to be converted to the relation between applied force and cell deformation \( (F \text{ vs. } \delta_c) \) by correcting cantilever deflection from the piezo displacement (Wang et al., 2012a,b, 2015). According to the spherical Hertzian contact mechanical model, the constitutive relation for a rigid spherical probe with radius of \( R_{AFM} \) pressing vertically on an elastic half continuum with elastic modulus, \( E \), and Poisson’s ratio, \( \nu = 0.50 \), is used to compute the cell elastic modulus, given by

\[
E = \frac{3}{4} \frac{1 - \nu^2}{R_{AFM}} \frac{\partial F}{\partial (\delta_c^{3/2})}.
\]

An in-house-developed MATLAB (MathWorks, Inc., Natick, MA, USA) code was used to obtain elasticity maps by analyzing all 1024 force curves in each force-volume mapping, where the fitting goodness values \( R^2 \) exceeded 0.9 in all curve fittings. A line of zero force was defined from the average deflection of points on the force-displacement curve corresponding to the positions of the cantilever when it was far away from the surface.

### 2.7. Trichrome staining and hydroxyproline assay

Six-micrometer-thick tissue sections were prepared from tumors and normal breast tissues. Total collagen was stained using trichrome staining kit (Sigma) as per the manufacturer’s instructions. To quantitate collagen content, levels of hydroxyproline were measured in tissues using Hydroxyproline assay kit (Sigma). Briefly, 10 mg of tumorous or normal breast tissues was homogenized in 100 mL of water and hydrolyzed in 12 m concentrated HCl at 120 °C for 3 h. Twenty-five microlitre of supernatant was transferred to 96-well plate and dried at 60 °C in an oven. Hundred microlitre of chloramine T/oxidation buffer mixture was added to each sample and standard well and incubated at room temperature for 5 min. Further, 100 \( \mu \)L of the diluted DMAB reagent was added to well and incubated for 90 min at 60 °C. Absorbance was taken at 560 nm.

### 2.8. Western blot

Total protein lysates were prepared using NP-40 lysis buffer containing protease inhibitor. Cell lysates were centrifuged for 30 min at 4 °C at 16,000 \( g \) to remove cellular debris. Protein concentrations were determined using Bradford assay. Immunoblotting was performed under native conditions for anti-collagen IV antibody (Abcam) using 40 \( \mu \)g of proteins. After primary antibody incubation, membranes were incubated with IR secondary antibody (Licor) and signals were detected using Odyssey® infrared imaging system (LI-COR Biosciences, Lincoln, NE, USA).

### 2.9. Glycosylation staining

For glycosylation staining, tissue sections were processed for deparaffinization and antigen retrieval as described above in IHC methodology. DIG glycan differentiation kit (Roche Applied Science, Indianapolis, IN, USA) was used for the detection of O- and N-linked glycosylation. Two different digoxigenin (DIG)-labeled plant lectins *Sambucus nigra agglutinin* (SNA), identifies N-linked glycosylation, and *peanut agglutinin* (PNA), identifies O-linked glycosylation, were used. Briefly, tissue sections were blocked with a blocking buffer and washed in Tris buffer saline, 0.5% Tween-20 (TBST), and buffer 1 (TBS, 1 \( \mathrm{mm} \) MgCl\(_2\), 1 \( \mathrm{mm} \) MnCl\(_2\), 1 \( \mathrm{mm} \) CaCl\(_2\), pH 7.5). After washing, the sections were incubated overnight with DIG-labeled SNA (10 \( \mu \)g.mL\(^{-1}\)) and PNA (40 \( \mu \)g.mL\(^{-1}\)) lectins at 4 °C. After washing with TBST, the sections were incubated with 2 \( \mu \)L.mL\(^{-1}\) anti-DIG-alkaline phosphatase for 1 h at room temperature. Tissue sections were incubated with 20 \( \mu \)L.mL\(^{-1}\) nitro-blue-tetrazolium chloride/5-bromo-4-chloro-3-indolyl-phosphate (NBT/BCIP) staining solution in buffer 2 (0.1 \( \mathrm{m} \) Tris/HCl, 0.05 \( \mathrm{m} \) MgCl\(_2\), 0.1 \( \mathrm{m} \) NaCl, pH 9.5) for 3–5 min at room temperature. Upon development of dark brown/blue color, the reaction was stopped using ultra-pure water. Western blot was also performed using same DIG glycan kit. Equal amount of protein from normal breast tissues was used for SDS/PAGE. After protein transfer, membranes were blocked and processed using the same reagents and methods as described above for tissue sections.
2.10. *In vivo* tumor generation

Tumors were generated as described before (Katara *et al.*, 2016). Briefly, E0771 or Py230 mouse mammary carcinoma cells ($5 \times 10^5$ in 50 µL PBS) were inoculated subcutaneously into the left fourth abdominal mammary fat pad of 6- to 8-week-old female a2Vfl/fl, a2Vfl/flMMTVCre, and a2Vfl/flMMTVCre mice.

2.11. siRNA mediated knockdown of a2V

HMEpC ($3 \times 10^5$) cells were plated in 8-chamber slides and transfected with three independent anti-a2V siRNA (a) rGrCrCrUrUrArUrGrArCrUrArGrCr CrArArUrArUrArUTC, (b) rArCrArGrUrUrArAr ArGrArGrUrArUrGrUrGrArUTG, and (c) rAr GrCrUrGrUrArCrArArArArGrArGrArUrGrGrArUTG) and scrambled control siRNA (OriGene, Rockville, MD, USA). Lipofectamine 3000 (Invitrogen) was used as a transfection reagent according to the manufacturer’s instructions.

2.12. Statistical analysis

Statistical significance was calculated for each subset by Mann–Whitney test/unpaired *t*-test using GraphPad PRISM 5 (GraphPad Software Inc., La Jolla, CA, USA). Collagen density was calculated as the proportion of blue collagen staining in each field of view in the Masson’s trichrome staining using IMAGEJ (National Institutes of Health, Rockville, MD, USA). Sample size for animal experiments was determined by power calculation. Sample size for animal experiments was determined by power calculation. The investigators were not blinded to sample identity or results.

3. Results

3.1. Tumors in a2V-knockout breast tissues exhibit soft phenotype and increased metastasis

To understand the role of host-associated a2V in breast cancer, we generated mammary epithelial cellspecific a2V-knockout (a2Vfl/flMMTVCre) mice (Fig. 1A, Fig. S1A). We observed a significant reduction in a2V mRNA levels in epithelial cells, isolated from mammary glands of a2Vfl/flMMTVCre mice compared to wild-type (a2Vfl/fl) mice (Fig. 1B). The deletion of a2V in a2Vfl/flMMTVCre mice did not alter gene expression of any other isoform of ‘a’ subunits (a1, a3, and a4) in the mammary gland (Fig. S1B). At the protein level, a2V was specifically deleted in the mammary epithelia of breast tissue as determined by immunohistochemistry (IHC) (Fig. 1C). In IFA, the absence of a2V protein (green) in a2Vfl/flMMTVCre mice confirms the deletion of floxed a2V gene (a2Vfl/fl) by Cre recombinase (red) (Fig. 1D). These a2Vfl/flMMTVCre mice were followed up to 1 year of age to check for viability, fertility, and any sign of external abnormality due to the a2V deletion. The vital organs including heart, lungs, liver, spleen, and intestine appeared normal (data not shown).

To determine how the absence of a2V in mammary glands influences breast cancer growth, we used a transplant tumor model. E0771 and/or Py230 mouse mammary adenocarcinoma cells were inoculated into the mammary glands of a2Vfl/flMMTVCre, a2Vfl/+MMTVCre, and a2Vfl/fl mice. E0771 cells generate tumors that are phenotypically and functionally similar to human breast tumors (Ewens *et al.*, 2005). Py230 cells are derived from MMTV-PyMT (mouse mammary tumor virus promoter-driven polyoma middle T-antigen) spontaneous tumor mouse and a well-established model for studying metastasis (Biswas *et al.*, 2014). In contrast to the solid primary breast tumor morphology typically observed in a2Vfl/fl mice, tumors in a2Vfl/flMMTVCre mice appeared softer, more vascularized, and hemorrhagic with serous fluid (Fig. 2A).

The phenotypic differences between these tumors were further confirmed by histopathological evaluations. The results revealed that tumors from a2Vfl/fl mice displayed a confluent sheet of viable tumor cells with microscopic foci of tumor necrosis. A dense infiltrate of neoplastic cells invading into adjacent adipose tissue and a scattered infiltrate of neutrophils and mononuclear cells were present (Fig. 2B). In contrast, a2Vfl/flMMTVCre tumors showed residual microscopic nests of viable tumor cells. Many sections revealed extravasated red blood cells with large zones of hemorrhagic necrosis. A dense inflammatory infiltrate including neutrophils and mononuclear cells was also observed, suggestive of restricted cancer cell proliferation in local microenvironment (Fig. 2B). To confirm this phenomenon, we examined cancer cells in tumor sections by IHC. A constricted area of focus with a significantly low number of GFP-positive cancer cells at the primary tumor site in a2Vfl/flMMTVCre mice (Fig. 2C, *P* = 0.007). To confirm necrosis in tumors, we analyzed TNF-α expression in tumor sections by IHC. Tumor tissues from a2Vfl/flMMTVCre mice showed significantly higher numbers of TNF-α-positive cells compared to control (Fig. 2D, *P* = 0.007), confirming an increased necrosis in tumor microenvironment in the absence of a2V. More interestingly, these mice showed increased...
metastasis of tumors compared to control as evident by liver and lung tissue lesions and cytokeratin (Ck)14 staining of lung tissue (Fig. 2E,F, Fig. S2). Quantitation of Ck14 staining in lung tissues showed 3.3-fold increase in Ck14-positive cells in a2Vfl/flMMTVCre mice compared to control (Fig. 2F, \( P = 0.004 \)). These data indicated the localized inhibition of tumor cell proliferation in the absence of host a2V. However, these tumors were more invasive and metastatic, suggesting the involvement of host microenvironment in metastasis. Therefore, we aimed to characterize the composition of ECM in normal breast tissues of a2Vfl/flMMTVCre mice.

### 3.2. a2V deletion in mammary glands causes alterations in structure and stiffness of ECM

We next examined the normal breast tissues from a2Vfl/flMMTVCre mice for any structural changes due to a2V deletion. Histological evaluation revealed a...
clear difference in breast tissue architecture between the a2Vfl/fl and a2Vfl/flMMTVCre mice (Fig. 3A). In the a2Vfl/fl mice tissue, ductal structures were obvious, cell and ECM density was greater, while in a2Vfl/flMMTVCre mice there were a limited ductal development and thin ECM (Fig. 3A). These results suggested a thin and less dense ECM in a2Vfl/flMMTVCre mice. To further confirm the density difference in ECM, we analyzed the nanomechanical properties of breast tissues by atomic force microscopy (AFM). The results of AFM revealed a characteristic homogeneous unimodal stiffness distribution with a single peak in breast tissues from both a2Vfl/flMMTVCre and a2Vfl/fl mice. However, we observed lower stiffness values in a2Vfl/flMMTVCre breast tissues (0.10 ± 0.01 kPa) compared to control (0.22 ± 0.04 kPa) (mean ± SD, P = 0.001) (Fig. 3B). These data provide additional evidence that a2V deletion causes stiffness-related alteration in a2Vfl/flMMTVCre mice.

Tumor stiffness is inversely correlated with cancer metastasis (Plodinec et al., 2012), and in a2Vfl/flMMTVCre mice, we observed more metastasis than

**Fig. 3.** Breast tissue ECM of a2V-knockout (a2Vfl/flMMTVCre) mice displays reduced density and stiffness: (A) Representative images showing ECM density difference (black arrow head) in breast tissue sections from a2Vfl/fl or a2Vfl/flMMTVCre mice by hematoxylin and eosin staining. n = 8, magnification 4× and 20×, scale bar 500 and 100 μm. (B) Stiffness distribution of normal breast tissues from a2Vfl/fl or a2Vfl/flMMTVCre mice measured by atomic force microscopy. Single peaks demonstrate characteristic unimodal stiffness profile of normal breast tissue. Tissue stiffness data are represented in kPa, mean ± SD, n = 5, *P < 0.05. (C) Representative images of Mason trichrome staining of total collagen content in normal as well as tumorous breast tissues from a2Vfl/fl or a2Vfl/flMMTVCre mice. The blue color shows staining for collagen protein, and red color shows cytoplasm. n = 7 each group, magnification 10×, scale bar 200 μm. Graph shows quantification of collagen density. Values are presented as mean ± SE, n = 7 each group, *P < 0.05. (D) Graph shows total hydroxyproline amino acid content in normal as well as tumorous breast tissues from a2Vfl/fl or a2Vfl/flMMTVCre mice measured by hydroxyproline assay. Values presented as mean ± SE, n = 12 and 15, *P < 0.05. (E) Representative images of immunofluorescence analysis of collagen IV protein expression in normal breast tissue sections from a2Vfl/fl or a2Vfl/flMMTVCre mice. The red color shows positive staining for collagen IV protein, and blue color shows DAPI staining for the nucleus, magnification 10×, scale bar 200 μm. (F) Western blot showing collagen IV protein expression in protein lysates prepared from a2Vfl/fl or a2Vfl/flMMTVCre mice breast tissues. n = 3 each group, *P < 0.05. Protein concentrations were normalized using β-actin.
a2V/β1 mice. Therefore, in addition to normal breast tissues, we also examined tumorous tissues for microscopic stiffness using AFM. Sequential stiffness maps across the specimen showed characteristic heterogeneity in tumor tissues from both a2V/β1/MMTVCre and a2V/β1 mice. However, lesser stiffness as well as heterogeneity was observed in a2V/β1/MMTVCre tumors as peak varies from 0.56 ± 0.11 kPa to 2.11 ± 0.16 kPa. In a2V/β1 tumors, peaks varied from 0.22 ± 0.18 kPa to 3.24 ± 0.22 kPa (mean ± SD) (Fig. S3). These data provide additional evidence that tumors in a2V knockout were softer and a2V deletion causes stiffness-related alterations in breast tissues of these mice.

3.3. Loss of a2V reduces the production of ECM proteins by mammary epithelial cells

We next examined the status of ECM proteins as the possible reason for the compromised ECM production due to a2V deletion in mammary epithelial cells. In breast tissue ECM, collagen is the most abundant protein and collagen IV and laminins are important glycoproteins which are secreted by mammary epithelial cells to maintain the structural organization of ECM (Maller et al., 2010). Mason trichrome staining, which reacts with collagen, showed a significant decrease in the total collagen content in both normal and tumorous breast tissues of a2V/β1/MMTVCre mice (Fig. 3C, P = 0.015 and Fig. S4A, P = 0.03). In a2V/β1 mice, most of the collagen was organized into large tracks of aligned fibrils, whereas a2V/β1/MMTVCre mice showed disorganized collagen bundles in breast tissues. Total collagen content was also measured by quantitating amount of hydroxyproline in tissue lysates prepared from breast tissues. Results of hydroxyproline assay confirmed a significant reduction in the collagen content in both normal (mean ± SE, 15.31 ± 0.8903 ng·μL⁻¹, n = 15) and tumors (31.15 ± 2.700, n = 5) breast tissues of a2V/β1/MMTVCre mice compared to control (normal; 25.65 ± 1.773, n = 16, tumor; 57.15 ± 3.853, n = 5) (Fig. 3D, Fig. S4B). As a2V expression was inhibited in epithelial cells only, we examined the status of epithelial cell producing collagen IV and laminin proteins in these breast tissues. IFA of breast tissues revealed a significantly low production of collagen IV in a2V/β1/MMTVCre mice (Fig. 3E, P = 0.01). Immunoblotting of collagen IV in protein lysates prepared from breast tissues also confirmed low production of collagen IV in a2V/β1/MMTVCre mice (Fig. 3F, P = 0.03). Similarly, a low expression of laminin was also observed in breast tissues of a2V/β1/MMTVCre mice (Fig. S4C, P = 0.03).

These results show that a2V deletion causes defects in ECM through reducing the production of matrix proteins required for proper composition.

3.4. Inhibition of a2V expression causes altered Golgi morphology and defective glycosylation in mammary epithelial cells

Next, we examined how the deletion of a2V leads to a low production of ECM proteins. a2V is present on Golgi membrane and disruption of a2V functions leads to deformation in Golgi structure (Axelsson et al., 2001; Udono et al., 2015). We evaluated Golgi morphology in mammary epithelial cells of breast tissues from a2V/β1/MMTVCre mice by staining for giantin, which is a Golgi membrane protein. Results of IFA show a dispersed Golgi morphology in epithelial cells of mammary glands of a2V/β1/MMTVCre mice compared to a typical perinuclear location in a2V/β1 mice (Fig. 4A). No generic increase in giantin protein expression was observed in a2V/β1/MMTVCre mice due to a2V deletion (Fig. S5A). The structural deformation in Golgi is known to cause glycosylation defects in mammalian cells. Also, in ACRL patients, abnormal glycosylation of serum proteins is associated with loss-of-function mutation in the a2V gene (Fischer et al., 2012; Guillard et al., 2009; Kornak et al., 2008). To determine whether a similar phenomenon occurs in our model, we examined the protein glycosylation defects in ECM of normal breast tissue. During post-translational modifications, proteins are glycosylated inside Golgi and carbohydrate chains are attached at specific positions to these proteins in the presence of glycosyltransferases (Breton et al., 2006). O- and N-linked are the two major types of glycosylations and various mammary gland ECM proteins are glycosylated at these positions (Burchell et al., 2001; Vijay, 1998). Lectins SNA and PNA were used to identify O- and N-linked protein glycosylation, respectively, in breast tissues. Results of glycoprotein IHC in breast tissues showed a significantly reduced staining for both SNA and PNA lectins in a2V/β1/MMTVCre mice compared to control (Fig. 4B, P = 0.01, Fig. S5B). The glycosylation defects were also evaluated in mammary epithelial cells isolated from mice by immunoblotting. A reduction in glycosylation of proteins was also observed in protein lysates prepared from these cells by western blot (Fig. 4C).

Neutralization of Golgi pH causes relocation of glycosyltransferase enzymes from Golgi to endosomes or plasma membrane causing protein glycosylation-related changes in cells (Axelsson et al., 2001; Udono et al., 2015). Therefore, we evaluated any change in
the distribution of GL25D2, a galactosyltransferase that glycosylates collagen IV in Golgi, as a possible factor for glycosylation irregularities in a2Vfl/flMMTVCre mice. Results showed a dispersed distribution of GL25D2 throughout the cytoplasm in epithelial cells of a2Vfl/fl breast tissue, whereas in a2Vfl/flMMTVCre mice the enzyme showed a perinuclear location (Fig. 4D). This finding suggests the reduced availability of GL25D2 in Golgi for efficient glycosylation of proteins processed therein. These data confirmed that the inhibition of a2V expression in mammary epithelial cells of a2Vfl/fl mice the enzyme exhibits distribution all over the cell. n = 5 each group, magnification 100x, scale bar 20 µm.

3.5. Low a2V expression in normal breast is associated with metastatic disease in patients with breast cancer

To test the clinical relevance of our findings, we examined a2V expression levels in normal or metastatic breast tissue from patients with breast cancer. We observed a significant decrease in a2V expression in metastatic tissues compared to normal breast tissue (Fig. S7). This finding suggests that low a2V expression in normal breast is associated with an increased risk of metastatic disease in patients with breast cancer.

We next examined the cellular location of GL25D2 after inhibition of a2V expression. We used human primary mammary epithelial cells (HMEpC) and inhibited a2V expression using three independent anti-a2V siRNA. The efficiency of a2V knockdown was evaluated by quantitative RT-PCR and western blot (Fig. S6). These transfected HMEpC cells were then stained for GL25D2, EEA-1 (early endosome antigen), to determine GL25D2 distribution after a2V inhibition. We observed that a2V knockdown in primary mammary epithelial cells resulted in the relocation of GL25D2 to the early endosomes from the perinuclear location (Fig. 5A, Pearson’s correlation coefficient $r_p = 0.89 \pm 0.03$, $P = 0.01$), confirming alteration in Golgi functioning. These results confirm that the inhibition of a2V expression in mammary epithelial cells causes abnormal Golgi morphology and relocation of glycosyltransferases to early endosomes from Golgi. This results in defects in protein glycosylation and low production of ECM proteins that lead to the inadequate ECM formation (Fig. 5B).

3.5. Low a2V expression in normal breast is associated with metastatic disease in patients with breast cancer

To test the clinical relevance of our findings, we examined a2V expression levels in normal or metastatic breast tissue from patients with breast cancer.
uninvolved breast tissues from patients with cancer reported with lymph node metastasis (LNM) or no LNM of tumors. We observed that patients with LNM had a significantly lower expression of a2V in mammary glands of uninvolved or normal breast tissues compared to patients with no LNM of tumors (Fig. 6A, \( P = 0.02 \)). The total collagen was also stained in these tissues to determine whether low a2V expression levels have any effect on collagen content or organization. Results of Mason trichrome staining showed a lower deposition of total collagen in ECM of normal breast tissues in patients with LNM compared to no LNM patients (Fig. 6B, \( P = 0.03 \)). An inconsistency in collagen sheets around mammary epithelial cells was also observed in normal breast tissues from patients with LNM, suggesting stiffness-related alterations in ECM (Fig. 6B). H&E, a2V, and collagen staining procedures of normal breast and respective primary tumor tissues from same patients are shown in Fig. S7. These results indicate that a2V expression in mammary glands has an impact on ECM architecture and evaluation of a2V levels in normal breast tissues can help in predicting the metastatic fate of tumor cells.

**Fig. 5.** The loss of a2V causes relocation of galactosyltransferase from Golgi to endosome in mammary epithelial cells. (A) Representative images of colocalization of GL25D2 and EEA-1 (early endosome marker) by IFA in HMEpC cells. To inhibit a2V expression, HMEpC cells were treated with scrambled RNA control (Scr) or three different anti-a2V siRNAs (Si-a2). Cells were then stained with anti-EEA-1 (green) and anti-GL25D2 (red), magnification 100x, scale bar 20 μm. Efficiencies of all siRNAs were quantified by real-time PCR (see Fig. S5). Pearson’s correlation coefficient and scatter plot between EEA-1 and GL25D2 are also shown in this panel. \( n = 3 \) for each siRNA. (B) Schematic representing regulation of ECM composition by V-ATPase: under normal conditions (a2V\textsuperscript{fl/fl}), Golgi pH is maintained through the function of a2V. ECM proteins are produced and properly glycosylated by glycosyltransferases; these proteins are transported to extracellular space through secretory vesicles where they contribute to ECM composition. When a2V function is interrupted (a2V\textsuperscript{fl/flMMTVCre}), pH imbalance in Golgi results in a dispersed Golgi morphology (1) and relocation of glycosyltransferases to early endosomes and then to lysosomes (2). Due to the lack of effective glycosyltransferase activity in Golgi, ECM proteins are improperly glycosylated, which affects their production. These abnormally glycosylated proteins and glycosyltransferases are later transported to lysosomes for degradation.
4. Discussion

Although V-ATPase is essentially required for cancer progression and metastasis, relatively few studies have examined its functional role in breast cancer. The present study aimed to decipher the role of host-associated V-ATPase in breast cancer pathology. For the first time, this study provides an insight into the association of V-ATPase with ECM architecture in vivo by employing a unique experimental mouse model. Here, we have established that the absence of a2V in mammary gland causes abnormality in ECM composition and architecture that further augment breast cancer dissemination.

A stiff or dense ECM stimulates the transformation of epithelial cells from normal to malignant cancer cells (Calvo et al., 2013; Levental et al., 2009). It has been suggested that stiffer breast tissue tends to have a higher risk of breast cancer (McCormack and dos Santos Silva, 2006). The collagen protein content has been considered as a major contributor in ECM stiffness. However, in the mouse model, increased collagen cross-linking, but not collagen content, enhances ECM stiffness and cancer malignancy (Levental et al., 2009). Therefore, the correlation between collagen content and cancer outcome and/or metastases is still not clear. Studies have shown either an inverse relationship or failed to establish any correlation in humans (Eriksen et al., 2013; Gierach et al., 2012; Kakkad et al., 2012; Wasuthit et al., 2011). In the mouse, linearized collagen bundles increase cell migration, whereas a dense network of stiff matrix fibers hampers migration (Egeblad et al., 2010). Here, in a2Vfl/flMMTVCre mice, we observed an altered and less stiff ECM of normal

![Fig. 6](image-url)

Fig. 6. Evaluation of a2V expression and collagen protein in human normal breast: (A) representative IHC images showing a2V protein staining in normal or uninvolved breast tissues from breast cancer patients reported with lymph node metastasis (LNM) or no LNM of tumors. Brown color (black arrow head) shows positive staining for a2V, and blue color shows nuclear staining by counterstain hematoxylin. n = 5, left panel shows overall histology at lower magnification (4x), scale bar 500 μm. Representative images at higher magnification (40x) are shown in the right panel, scale bar 50 μm. Graph shows quantification of a2V-positive cells in breast tumors from LNM and no LNM breast cancer patients. Total number of a2V-positive cells per 40x view were counted. Mean of total 10 views was considered per sample. Values are presented as mean ± SE, n = 5 each group, *P < 0.05. (B) Representative images of Mason trichrome staining of total collagen content in same tissues. Black arrow head shows collagen sheets around mammary epithelial cells. Left panel shows overall histology at lower magnification (4x), scale bar 500 μm. Representative images at higher magnification (40x) are shown in the right panel, scale bar 50 μm. Graph shows quantification of collagen density. Values are presented as mean ± SE, n = 5 each group, *P < 0.05.
as well as tumorous breast tissue. We also observed less total collagen content and a lower expression of collagen IV and laminin in breast tissues of a2Vfl/fl MMTVCre mice. In breast tissue ECM, stromal collagen I, a fibrillar collagen, is secreted by fibroblasts, whereas basement membrane collagen IV is secreted by mammary epithelial cells. The adequate structure and functioning of collagen is dependent on the proper production and anchoring of these molecules. Abnormal glycosylation or other changes in any protein can lead to dysfunction of collagen protein, which finally affects the adequate cross-linking to other proteins and appropriate ECM architecture (Maller et al., 2010). Here, Masson’s trichrome staining, which reacts with all fibrillar collagen, confirmed a significant reduction in fibril-associated collagen in a2Vfl/fl MMTVCre mice. We speculate that less secretion of collagen IV by epithelial cells can lead to the degradation of fibroblast-secreted collagen I and results in the reduction in total collagen content in breast tissue. In basal lamina, collagen IV cross-links with laminin through nidogen glycoproteins and any change in collagen production can affect its binding with laminin (Mow et al., 2014). Further, like collagen IV, laminin is a glycosylated protein and secreted by epithelial cells. Here, the reduction in laminin expression can be a combinatorial effect of abnormal glycosylation in epithelial cells and the unavailability of collagen IV for cross-linking in ECM. This decrease in laminin expression can also contribute to increased metastasis in a2Vfl/fl MMTVCre mice as downregulation in laminin expression has been shown in various advanced breast cancers (Pouliot and Kusuma, 2013). In cutis laxa patients, mutation in V-ATPase-a2 gene leads to glycosylation defects in tropoelastin protein, which affects its secretion from fibroblast cells in skin. This tropoelastin protein further fails to create an adequate cross-linking with collagen and fibronectin which are required for proper ECM structure in skin (Guillard et al., 2009; Huethagowder et al., 2009). Loss of O-glycosylation in epithelial cells reduces the secretion of basement membrane collagen protein that affects ECM composition in submandibular gland in mice (Tian et al., 2012). Further, upon inhibition of V-ATPase function, Golgi pH and structure are disrupted and glycosyltransferases are relocated from Golgi to early endosomes or plasma membranes, resulting in glycosylation changes (Huethagowder et al., 2009; Kellokumpu et al., 2002; Udon et al., 2015). Our results are consistent with these studies as we found a similar glycosylation and compositional defects in ECM and dispersed Golgi morphology in mammary epithelial cells of a2Vfl/fl MMTVCre mice breast tissues. In addition, siRNA inhibition of a2V in epithelial cells results in relocation of GL25D2 to early endosomes, confirming the a2V-mediated protein glycosylation defects in a2Vfl/fl MMTVCre mice.

Cancer cells adhere to the ECM through various receptors and an abnormal ECM composition can lead to the failure in the establishment of a solid primary tumor phenotype (Lu et al., 2012). Here, a2Vfl/fl MMTVCre mice produced soft primary tumors and restricted cell proliferation as evident by the decreased number of GFP-positive cancer cells. Additionally, the presence of high TNF-α expression and necrotic tissue suggests greater-than-normal inflammatory responses in the local microenvironment in a2Vfl/fl MMTVCre mice. In a murine model of pancreatic cancer, SPARC gene deficiency caused a reduction in expression levels of types I, III, and IV collagen that led to elevated tumor metastases (Arnold et al., 2010). We speculate that due to the inadequacy of collagen and other proteins in ECM of a2Vfl/fl MMTVCre breast tissues, cancer cells failed to establish as solid primary tumors and inflammation at tumor sites restricted their localized growth. The altered ECM in these mice further helps cancer cells to escape inflammation and migrate to distant organs. The higher inflammatory infiltrate of leukocytes accompanied by increased metastases in a2Vfl/fl MMTVCre mice suggests an easy infiltration of immune cells as well as the migration of cancer cells from the tumor implantation site. In a2Vfl/fl MMTVCre mice, the soft tumor phenotype, low collagen content, and increased metastasis correlate with recent murine breast cancer studies showing that a ‘soft’ tumor tissue phenotype and low collagen content correspond to increased metastases (Fenner et al., 2014; Plodinec et al., 2012).

Clinically, we found that a2V expression may serve as a novel biomarker for breast cancer. a2V is highly expressed in primary tumors of patients with breast cancer (Fig. S6). Although there was a limited sample size for paired tissues from patients with breast cancer, we demonstrated that lower expression of a2V in normal or uninvolved breasts tissues correlates with the collagen disorganization in patients with metastatic breast cancer. In normal conditions, expression of various isoforms of V-ATPase was regulated at both transcriptional and post-transcriptional levels. Basal expression of V-ATPase ‘a3’ isoform has been shown to be suppressed by poly(ADP-ribose) polymerase-1 (PARP-1), a highly conserved nuclear protein that modulates chromatin structure and causes transcriptional inhibition (Beranger et al., 2006; Serrano et al., 2009). The involvement of 3’ untranslated regions and AU-rich element has been shown in post-transcriptional regulation of various V-ATPase isoforms.
A genome-wide analysis study revealed higher-efficiency miRNA binding sites in mRNA of ‘a1’ isoform of V-ATPase (O’Connor et al., 2008). This miRNA predicted to cause a reduction in a1 translation that further impairs the regulation of secretory pathway. The reduction in a2V mRNA levels in normal breast tissues of patients with LNM can be due to these factors that need to be investigated. The clinical significance of this finding warrants further investigation to determine particularly whether a2V expression defines a group of patients with risk of developing metastatic disease and whether they thus may require personalized therapy.

5. Conclusions

For the first time, this study establishes the direct link between breast tissue ECM stiffness and V-ATPase activity. These data show that host cell-associated V-ATPase expression levels can affect breast cancer dissemination, at least in part, through ECM remodeling. Considering the diverse role of ECM stiffness in cancer outcome, this study highlights a2V as an important regulatory molecule in cancer mechanics. The inclusion of a2V with other clinically relevant prognostic markers could efficiently help in the risk assessment of metastases and the designing of personalized therapy for patients with breast cancer.

Acknowledgements

This work made use of the SPID facility of the NUANCE Center at Northwestern University, which has received support from the Soft and Hybrid Nanotechnology Experimental (SHyNE) Resource (NSF NNCI-1542205); the MRSEC program (NSF DMR-1121262) at the Materials Research Center; the International Institute for Nanotechnology (IIN); the Keck Foundation; and the State of Illinois, through the IIN. We thank Dr. Mukesh Jaiswal for help with generating the a2V mouse mammary knockout model. We thank Sara Fleetwood for help in maintaining mouse colonies. We are grateful to the Mouse Histology and Phenotyping Laboratory at the Northwestern University, Chicago, for their technical help.

Author contributions

GKK and AK contributed to designing the research, performing the experiments, interpreting the data, making figures, and writing the manuscript. LM, MS, SI, and SP assisted in animal breeding and experiments for the study. XW and GSS assisted with AFM experiments and data analysis. KS analyzed and interpreted tissue pathology. AGS and KDB wrote and edited the manuscript and provided resources for study.

References

Arnold SA, Rivera LB, Miller AF, Carbon JG, Dineen SP, Xie Y, Castrillon DH, Sage EH, Puolakkainen P, Bradshaw AD et al. (2010) Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. Dis Model Mech 3, 57–72.

Axelsson MA, Karlsson NG, Steel DM, Ouwendijk J, Nilsson T and Hansson GC (2001) Neutralization of pH in the Golgi apparatus causes redistribution of glycosyltransferases and changes in the O-glycosylation of mucins. Glycobiology 11, 633–644.

Beranger GE, Monier D, Rochet N, Quincey D, Guigonis JM, Samson M, Carle GF and Scimeca JC (2006) RANKL treatment releases the negative regulation of the poly(ADP-ribose) polymerase-1 on Tcirg1 gene expression during osteoclastogenesis. J Bone Miner Res 21, 1757–1769.

Biswas T, Gu X, Yang J, Ellies LG and Sun LZ (2014) Attenuation of TGF-beta signaling supports tumor progression of a mesenchymal-like mammary tumor cell line in a syngeneic murine model. Cancer Lett 346, 129–138.

Bonnans C, Chou J and Werb Z (2014) Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol 15, 786–801.

Breton S and Brown D (2013) Regulation of luminal acidification by the V-ATPase. Physiology (Bethesda) 28, 318–329.

Breton C, Snajdrova L, Jeanneau C, Koca J and Imberty A (2006) Structures and mechanisms of glycosyltransferases. Glycobiology 16, 29R–37R.

Burchell JM, Mungul A and Taylor-Papadimitriou J (2001) O-linked glycosylation in the mammary gland: changes that occur during malignancy. J Mammary Gland Biol Neoplasia 6, 355–364.

Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI, Harrington K, Williamson P, Moeendarbary E, Charras G et al. (2013) Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol 15, 637–646.

Derks R and Beaman K (2004) Regeneration and tolerance factor modulates the effect of adenosine triphosphate-induced interleukin 1 beta secretion in human macrophages. Human Immunol 65, 676–682.

Egeblad M, Rasch MG and Weaver VM (2010) Dynamic interplay between the collagen scaffold and tumor evolution. Curr Opin Cell Biol 22, 697–706.
V-ATPase regulates metastasis by ECM remodeling

G. K. Katara et al.

Eriksson L, Czene K, Rosenberg L, Humphreys K and Hall P (2013) Possible influence of mammographic density on local and locoregional recurrence of breast cancer. *Breast Cancer Res* **15**, R56.

Ewens A, Mihich E and Ehrke MJ (2005) Distant metastases from subcutaneously grown E0771 medullary breast adenocarcinoma. *Anticancer Res* **25**, 3905–3915.

Fenner J, Stacer AC, Winterroth F, Johnson TD, Luker KE and Luker GD (2014) Macroscopic stiffness of breast tumors predicts metastasis. *Sci Rep* **4**, 5512.

Fischer B, Dimopoulou A, Egerer J, Gardeitchik T, Kidd A, Jost D, Kayserili H, Alayn Y, Tantecheva-Poor I, Mangold E et al. (2012) Further characterization of ATP6V0A2-related autosomal recessive cutis laxa. *Human Genet* **131**, 1761–1773.

Forgac M (2007) Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology. *Nat Rev Mol Cell Biol* **8**, 917–929.

Gierach GL, Ichikawa L, Kerlikowske K, Brinton LA, Farhat GN, Vacek PM, Weaver DL, Schairer C, Taplin SH and Sherman ME (2012) Relationship between mammographic density and breast cancer death in the Breast Cancer Surveillance Consortium. *J Natl Cancer Inst* **104**, 1218–1227.

Guillard M, Dimopoulou A, Fischer B, Morava E, Lefeber DJ, Kornak U and Wevers RA (2009) Vacuolar H+-ATPase meets glycosylation in patients with cutis laxa. *Biochim Biophys Acta* **1792**, 903–914.

Huethergowder V, Morava E, Kornak U, Lefeber DJ, Fischer B, Dimopoulou A, Aldinger A, Choi J, Davis EC, Abuol DN et al. (2009) Loss-of-function mutations in ATP6V0A2 impair vesicular trafficking, tropoelastin secretion and cell survival. *Human Mol Genet* **18**, 2149–2165.

Hutter JL and Bechhofer J (1993) Calibration of atomic-force microscope tips. *Rev Sci Instrum* **64**, 3342.

Jeyaraj S, Dakhlahla D, Hill SR and Beaman KD (2014) Impaired glycosylation and altered Golgi structure in colorectal cancer: dependence on intra-Golgi pH. *FEBS Lett* **561**, 217–224.

Kornak U, Reinders E, Dimopoulou A, van Reeuwijk J, Fischer B, Rajab A, Budde B, Nurnberg P, Fouliquer F, Lefeber D et al. (2008) Impaired glycosylation and cutis laxa caused by mutations in the vesicular H+-ATPase subunit ATP6V0A2. *Nat Genet* **40**, 32–34.

Kulshrestha A, Katara GK, Ginter J, Pamartthy S, Ibrahim SA, Jaiswal MK, Sandulescu C, Periakaruppan R, Dolan J, Gilman-Sachs A et al. (2016) Selective inhibition of tumor cell associated Vacuolar-ATPase ‘a2’ isoform overcomes cisplatin resistance in ovarian cancer cells. *Mol Oncol* **10**, 789–805.

Kulshrestha A, Katara GK, Ibrahim S, Pamartthy S, Jaiswal MK, Gilman Sachs A and Beaman KD (2015) Vacuolar ATPase ‘a2’ isoform exhibits distinct cell surface accumulation and modulates matrix metalloproteinase activity in ovarian cancer. *Oncotarget* **6**, 3797–3810.

Levental KR, Yu H, Kass L, Lukins JN, Egeblad M, Erler JT, Fong SF, Csizsar K, Giaccia A, Wener W et al. (2009) Matrix crosslinking forces tumor progression by enhancing integrin signaling. *Cell* **139**, 891–906.

Liotta LA and Kohn EC (2001) The microenvironment of the tumour-host interface. *Nature* **411**, 375–379.

Lu P, Takai K, Weaver VM, Werb Z (2011) Extracellular matrix degradation and remodeling in development and disease. *Cold Spring Harb Perspect Biol* **3**, a005058.

Lu P, Weaver VM and Werb Z (2012) The extracellular matrix: a dynamic niche in cancer progression. *J Cell Biol* **196**, 395–406.

Maller O, Martinson H and Schedin P (2010) Extracellular matrix composition reveals complex and dynamic stromal-epithelial interactions in the mammary gland. *J Mammary Gland Biol Neoplasia* **15**, 301–318.

McCormack VA and dos Santos Silva I (2006) Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. *Cancer Epidemiol Biomarkers Prev* **15**, 1159–1169.

Mouw JK, Ou G and Weaver VM (2014) Extracellular matrix assembly; a multiscale deconstruction. *Nat Rev Mol Cell Biol* **15**, 771–785.

O’Connor DT, Zhu G, Rao F, Taupenet L, Fung MM, Das M, Mahata SK, Mahata M, Wang L, Zhang K et al. (2008) Heritability and genome-wide linkage in US and australian twins identify novel genomic regions controlling chromogranin a: implications for secretion and blood pressure. *Circulation* **118**, 247–257.

Pamartthy S, Mao L, Katara GK, Fleetwood S, Kulshreshta A, Gilman-Sachs A and Beaman KD

population in the tumor microenvironment. *Oncogene* **35**, 1058–1065.

Kellokumpu S, Sormunen R and Kellokumpu I (2002) Abnormal glycosylation and altered Golgi structure in colorectal cancer: dependence on intra-Golgi pH. *FEBS Lett* **561**, 217–224.

Eriksson L, Czene K, Rosenberg L, Humphreys K (2005) Distant metastasis from subcutaneously grown E0771 medullary breast adenocarcinoma. *Anticancer Res* **25**, 3905–3915.
(2016) The V-ATPase a2 isoform controls mammary gland development through Notch and TGF-beta signaling. *Cell Death Dis* 7, e2443.

Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, Reinhart-King CA, Margulies SS, Dembo M, Boettiger D et al. (2005) Tensional homeostasis and the malignant phenotype. *Cancer Cell* 8, 241–254.

Plodinec M, Loparic M, Monnier CA, Obermann EC, Serrano EM, Ricofort RD, Zuo J, Ochotny N, Manolson MF and Howell GJ, Phillips C, Muench SP, Stransky L, Cotter K and Forgac M (2016) The function of V-ATPases in cancer. *Mol Cell* 12, 801–803.

Smith GA, Howell GJ, Phillips C, Muench SP, Ponnambalam S and Harrison MA (2016) Extracellular and luminal pH regulation by vacuolar H+-ATPase isoform expression and targeting to the plasma membrane and endosomes. *J Biol Chem* 291, 8500–8515.

Smith AN, Lovering RC, Futai M, Takeda J, Brown D and Karet FE (2003) Revised nomenclature for mammalian vacuolar-type H+-ATPase subunit genes. *Mol Cell* 12, 801–803.

Stransky L, Cotter K and Forgac M (2016) The function of V-ATPases in cancer. *Physiol Rev* 96, 1071–1091.

Tian E, Hoffman MP and Ten Hagen KG (2012) O-glycosylation modulates integrin and FGF signalling by influencing the secretion of basement membrane components. *Nature* 439, 346–349.

Tian X, Azpurua J, Hine C, Vaidya C, Myakishev-Rempel M, Ablaeva J, Mao Z, Nevo E, Gorbunova V and Seluanov A (2013) High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat. *Nature* 499, 346–349.

Udono M, Fujii K, Harada G, Tsuzuki Y, Kadowka K, Zhang P, Fujii H, Amano M, Nishimura S, Tashiro K et al. (2015) Impaired ATP6V0A2 expression contributes to Golgi dispersion and glycosylation changes in senescent cells. *Sci Rep* 5, 17342.

Vijay IK (1998) Developmental and hormonal regulation of protein N-glycosylation in the mammary gland. *J Mammary Gland Biol Neoplasia* 3, 325–336.

Wang X, Bleher R, Brown ME, Garcia JG, Dudek SM, Shekawat GS and Dravis VP (2015) Nano-biomechanical study of spatio-temporal cytoskeleton rearrangements that determine subcellular mechanical properties and endothelial permeability. *Sci Rep* 5, 11097.

Wang SP, Krits I, Bai S and Lee BS (2002) Regulation of enhanced vacuolar H+-ATPase expression in macrophages. *J Biol Chem* 277, 8827–8834.

Wang X, Li Y, Onnis-Hayden A, Gao C, Gu AZ and Wan KT (2012a) Correlation of macroscopic aggregation behavior and microscopic adhesion properties of bacteria strains using a dimensionless Tabor's parameter. *J Colloid Interface Sci* 374, 70–76.

Wang X, Najem JF, Wong SC and Wan KT (2012b) A nano-cheese-cutter to directly measure interfacial adhesion of freestanding nano-fibers. *J Appl Phys* 111, 024315.

Wasuthit Y, Kongdan Y, Suvikapakornkul R, Lertsithichai P and Chirappapha P (2011) Predictive factors of axillary lymph node metastasis in breast cancer. *J Med Assoc Thai* 94, 65–70.

### Supporting information

Additional Supporting Information may be found online in the supporting information tab for this article:

**Fig. S1.** Genotyping PCR and mRNA expression analysis of other isoforms of ‘a’ subunit.

**Fig. S2.** Tumors in a2Vfl/flMMTVCre mice displayed increased metastasis.

**Fig. S3.** Stiffness profile of tumors.

**Fig. S4.** Collagen profile of tumors and expression analysis of laminin in normal breast tissue.

**Fig. S5.** (A) Western blot showing Giantin protein (~367kd) expression in protein lysates prepared from purified mammary epithelial cells from breast tissues of a2Vfl/fl or a2Vfl/flMMTVCre mice. Protein concentrations were normalized using β-actin (45kd). (B) SNA lectin staining demonstrating glycosylation in breast tissues from a2Vfl/fl or a2Vfl/flMMTVCre mice. The lectin staining appears as dark blue/brown color, magnification 10×, scale bar 200 μm.

**Fig. S6.** siRNA mediated knockdown of a2V.

**Fig. S7.** Evaluation of a2V expression and collagen protein in human breast tissue: representative images of H&E, a2V and Mason Trichrome staining in paired normal breast and primary tumor tissue from breast cancer patients reported with lymph node metastasis (LNM) of no LNM of tumors (n = 5).